The second largest cause of death is cancer and it’s the therapy area with the highest amount of R&D spend. This significant investment reflects the expectation of a number of critical breakthroughs in the coming years that will significantly reduce human suffering.
Cancers can arise in many parts of the body, leading to a range of cancer types and, in some cases, spread to other parts of the body through the blood and lymph systems. In the last decade, the industry has witnessed an acceleration in drug approvals - in the US, for example, there were, on average, c.16 drug approvals per year between 2010-18, up from an average of 6 per year in the previous decade (2000-2009). This was a direct result of an increased resource allocation to the development of oncology therapies.
The proportion of total R&D expenditure committed to oncology has risen from 27% in 2010 to 35% in 2019 (according to Informa R&D Review 2019) and there are currently 700 oncology drugs in the late stage of development.
Cancer treatments are becoming more personalized as the use of biomarkers increases - Airfinity monitors, in real time, new developments from early discovery, pivotal trials and larger phase 3 trials, and performs dynamic modelling in order to predict the future therapy success within different types of cancers.
We deliver critical data, information and insights to global decision makers across pharmaceuticals, med- and biotech companies, governments, corporates and investors.
Our experts will:
Complete the form to schedule your demo.